Bayhill Therapeutics
Founded Year
2000Stage
Dead | DeadTotal Raised
$97.35MAbout Bayhill Therapeutics
Bayhill Therapeutics Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics that fundamentally alter the way autoimmune diseases are treated. The company has developed two therapeutic platforms with broad applicability to a range of autoimmune diseases. Bayhill's BHT-DNA autoimmune vaccine is designed to eliminate disease-causing cells without effecting normal protective immune system cells. BHT-DNA is being studied in a Phase II trial for multiple sclerosis and a Phase I/II trial for autoimmune diabetes. Bayhill's second therapeutic is an oligonucleotide in preclinical development for systemic lupus erythematosus.
Loading...
Loading...
Bayhill Therapeutics Patents
Bayhill Therapeutics has filed 2 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/21/2003 | 10/12/2010 | Cannabinoids, Inflammations, Designer drugs, Indoles, Clusters of differentiation | Grant |
Application Date | 11/21/2003 |
|---|---|
Grant Date | 10/12/2010 |
Title | |
Related Topics | Cannabinoids, Inflammations, Designer drugs, Indoles, Clusters of differentiation |
Status | Grant |
Bayhill Therapeutics Frequently Asked Questions (FAQ)
When was Bayhill Therapeutics founded?
Bayhill Therapeutics was founded in 2000.
Where is Bayhill Therapeutics's headquarters?
Bayhill Therapeutics's headquarters is located at 1810 Gateway Drive, San Mateo.
What is Bayhill Therapeutics's latest funding round?
Bayhill Therapeutics's latest funding round is Dead.
How much did Bayhill Therapeutics raise?
Bayhill Therapeutics raised a total of $97.35M.
Who are the investors of Bayhill Therapeutics?
Investors of Bayhill Therapeutics include Latterell Venture Partners, U.S. Venture Partners, Morgenthaler Ventures, Presidio Partners, The Vertical Group and 10 more.
Who are Bayhill Therapeutics's competitors?
Competitors of Bayhill Therapeutics include ERYtech Pharma, La Jolla Pharmaceutical Company, Apitope, Endocyte, Biosceptre International and 7 more.
Loading...
Compare Bayhill Therapeutics to Competitors
REGiMMUNE is a biotechnology company focused on the discovery, development and commercialization of immune regulatory therapeutics to treat conditions such as allergies, autoimmune diseases and inflammatory disorders.
Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.
Dare Bioscience operates a healthcare company. Its commitment is to develop and commercialize innovative products in women's reproductive health. Dare Bioscience was formerly known as Tempo Pharmaceuticals. The company was founded in 2005 and is based in San Diego, California.
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.
DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's approach is based on the discovery of an innate IgM-mediated auto-immune pathway that is triggered by vascular injury in conditions such as diabetic nephropathy, sickle cell disease, and myocardial infarction. This pathway, dubbed N2, can initiate a cascade of tissue damaging events leading to loss of organ function.
LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.
Loading...